MDGL

Madrigal Pharmaceuticals
D

MDGL

486.56
USD
-5.94
(-1.21%)
مغلق
حجم التداول
11,205
الربح لكل سهم
-7
العائد الربحي
-
P/E
-36
حجم السوق
11,217,961,443
أصول ذات صلة المقالات
المزيد

العنوان: Madrigal Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.